BU

BUKWANG PHARMACEUTICAL IND CO.,LTD

An R&D-focused company developing drugs for CNS disorders and oncology.

003000 | KO

Overview

Corporate Details

ISIN(s):
KR7003000007
LEI:
Country:
South Korea
Address:
서울특별시 동작구 대방동1길 47, 서울특별시

Description

Bukwang Pharmaceutical is a research and development-focused company that develops, produces, and sells a range of pharmaceutical and oral hygienic products. The company emphasizes an open innovation strategy, leveraging joint ventures, research collaborations, and strategic investments to build a robust drug pipeline. Its key development areas include treatments for central nervous system disorders like schizophrenia, bipolar depression, and dyskinesia in Parkinson's disease. The pipeline also features oncology candidates, such as a treatment for metastatic prostate cancer. Bukwang Pharmaceutical manufactures various dosage forms, including oral solids and injections, alongside over-the-counter medications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-02 00:00
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Korean 114.4 KB
2025-05-30 00:00
임원ㆍ주요주주특정증권등거래계획보고서
Korean 46.2 KB
2025-05-30 00:00
임원ㆍ주요주주특정증권등거래계획보고서
Korean 46.3 KB
2025-05-30 00:00
임원ㆍ주요주주특정증권등거래계획보고서
Korean 46.2 KB
2025-05-29 00:00
[발행조건확정]증권신고서(지분증권)
Korean 112.5 KB
2025-05-29 00:00
유상증자신주발행가액(안내공시)
Korean 9.9 KB
2025-05-29 00:00
[기재정정]주요사항보고서(유상증자결정)
Korean 44.3 KB
2025-05-29 00:00
[기재정정]투자설명서
Korean 2.5 MB
2025-05-23 00:00
투자설명서
Korean 2.4 MB
2025-05-08 00:00
분기보고서 (2025.03)
Korean 1.5 MB
2025-05-08 00:00
[기재정정]증권신고서(지분증권) (2025.07)
Korean 3.0 MB
2025-04-25 00:00
[기재정정]증권신고서(지분증권) (2025.07)
Korean 3.1 MB
2025-04-22 00:00
연결재무제표기준영업(잠정)실적(공정공시)
Korean 18.9 KB
2025-04-18 00:00
기업설명회(IR)개최(안내공시)
Korean 6.1 KB
2025-04-11 00:00
[기재정정]증권신고서(지분증권) (2025.07)
Korean 3.2 MB

Automate Your Workflow. Get a real-time feed of all BUKWANG PHARMACEUTICAL IND CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BUKWANG PHARMACEUTICAL IND CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BUKWANG PHARMACEUTICAL IND CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.